University of Tennessee, Knoxville

TRACE: Tennessee Research and Creative
Exchange
Doctoral Dissertations

Graduate School

12-1999

Molecular and genetic analysis of the orpk mouse model of
polycystic kidney disease : searching for treatments and modifer
genes
Carla S. Sommardahl

Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss

Recommended Citation
Sommardahl, Carla S., "Molecular and genetic analysis of the orpk mouse model of polycystic kidney
disease : searching for treatments and modifer genes. " PhD diss., University of Tennessee, 1999.
https://trace.tennessee.edu/utk_graddiss/7481

This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee
Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized
administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact
trace@utk.edu.

To the Graduate Council:
I am submitting herewith a dissertation written by Carla S. Sommardahl entitled "Molecular and
genetic analysis of the orpk mouse model of polycystic kidney disease : searching for
treatments and modifer genes." I have examined the final electronic copy of this dissertation for
form and content and recommend that it be accepted in partial fulfillment of the requirements
for the degree of Doctor of Philosophy, with a major in Comparative and Experimental Medicine.
J. Erby Wilkinson, Major Professor
We have read this dissertation and recommend its acceptance:
Dabney K. Johnson, David O. Slauson, Edward J. Michaud
Accepted for the Council:
Carolyn R. Hodges
Vice Provost and Dean of the Graduate School
(Original signatures are on file with official student records.)

To the Graduate Council:
I am submitting herewith a dissertation written by Carla S. Sommardahl entitled
"Molecular and Genetic Analysis of the orpk Mouse Model of Polycystic Kidney
Disease: Searching for Treatments and Modifier Genes." I have examined the
final copy of this dissertation for form and content and recommend that it be
accepted in partial fulfillment of the requirements for the degree of doctor of
Philosophy, with a major in Comparative Experimental Medicine.

We have read this dissertation
and recommend its acceptance:

David 0. Slauson

Accepted for the Council:

Associate Vice Chancellor and
Dean of the Graduate School

Molecular and Genetic Analysis of the orpk Mouse
Model of Polycystic Kidney Disease: Searching for
Treatments and Modifier Genes

A Dissertation
Presented for the
Doctor of Philosophy
Degree
The University of Tennessee, Knoxville

Carla S. Sommardahl
December 1999

Copyright© Carla S. Sommardahl, 1999
All rights reserved

ii

DEDICATION
This dissertation is dedicated to my parents who gave me the genes and
environment to succeed in all my educational endeavors. Also, to my husband,
whose encouragement and help during these past very busy years, has enabled
me to reach this goal.

iii

ACKNOWLEDGEMENTS
I would like to thank Dr. Erby Wilkinson, my major professor for all his help
and encouragement toward this degree.

I would also like to thank the other

members of my Dissertation Committee, Dabney Johnson , who has guided me in
my research and who I hope continues to guide me; Dave Slauson, who is
always encouraging and understands my clinical perspective; and Ed Michaud,
who agreed to be a committee member at the last minute, but who has been a
friend and mentor for several years.
There are many people who assisted me in my work and I would like to
recognize and show my appreciation . I would like to thank Marilyn Cottrell and
Nancy Neilsen for all their technical help and advice. I thank the Department of
Pathology and the Department of Large Animal Clinical Sciences for allowing me
to be a graduate student and clinician at the same time. This allowed me to
maintain my skills as a veterinarian while I learned new skills as a researcher. I
have received generous financial support from the College of Veterinary
Medicine Center of Excellence and by the National Institute of Health National
Institute of Diabetes and Digestive and Kidney Disease grant #K08DK02466.
Lastly, I would like to thank Deb Haines and Tommy Jordan for all their help in
the preparation of the figures and photographs in this dissertation.

iv

Abstract

The orpk line of mice was previously identified as a unique model for human
polycystic kidney disease.

The most prominent phenotype is the invariable

development of bilateral polycystic kidneys and abnormalities in the intrahepatic
biliary tract and pancreas.
Taxol has been reported to be of therapeutic benefit in the cpk mouse model
of polycystic kidney disease. The effects of taxol treatment on the development
of renal cysts and biliary dysplasia/hyperplasia in the orpk mouse mutant were
studied. There were no significant differences between the treatment and control
groups with respect to weight gain, survival, urine to serum osmolality ratio, and
serum concentration of liver enzymes. Moreover, the renal cystic development
and biliary hyperplasia was not affected by taxol treatment in the orpk mutant
animals .
There are marked differences in the phenotypic expression of the orpk
mutation when bred on different genetic backgrounds.

In the FVB/N genetic

background, the phenotype is very severe in the kidney, liver, and pancreas
lesions.

To better evaluate how genetic background might influence the

expressivity of the orpk phenotype, the transgene was made congenic on the
C3H genetic background. Congenic orpk-C3H mutant mice have a much less
sever phenotype identical to that initially observed in the first generation
backcross to C3H. The kidney lesions are morphologically similar in the orpkC3H mutant mice, but they develop renal cysts at a slower rate and have fewer
cysts at all stages of cyst development. These animals also retain their renal
V

concentrating ability. The liver lesions in the orpk-C3H mutant animals are less
aggressive and are characterized by multifocal biliary hyperplasia, dysplasia, and
portal fibrosis isolated to the portal triad regions. The significant lesions when
the orpk mutation is on a different genetic background suggests the presence of
important modifier genes that vary in the FVB/N and C3H genetic backgrounds.
Whole genome quantitative trait analysis was performed to determine the
chromosomal location of the modifier genes that influence the phenotypic
expression of the orpk in the FVB/N and C3H genetic backgrounds. The percent
of the kidney that is cystic was used as a quantitative trait that reflects the kidney
phenotype.

Serum concentration of alkaline phosphatase was used as a

quantitative trait that reflects the liver phenotype.

A backcross between (orpk-

FVB X C3H) F1 tg/+ mice and orpk-FVB tg/+ mice was performed and 100 tg/tg
progeny were scored for the kidney and liver traits.
Whole genome quantitative trait loci mapping of 40 selected backcross tg/tg
progeny (20 with mild kidney scores and 20 with severe kidney scores) identified
three chromosomal intervals that segregated with the severe kidney phenotype.
Whole genome quantitative trait loci mapping of 40 selected backcross tg/tg
progeny (20 with mild liver scores and 20 with severe liver scores) identified one
DNA marker that segregated with the severe liver phenotype.

Further

characterization of these intervals with low resolution and fine mapping may
provide candidate modifying loci that will provide information in understanding the
pathogenesis of polycystic kidney disease.
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I. INTRODUCTION
Polycystic Kidney Disease

Description and incidence
The formation of renal cysts is common to several genetic disorders in
humans [1-3]. As a group, polycystic kidney diseases (PKO) account for over

10% of all patients requiring chronic dialysis or kidney transplantation [2 ;4]. The
predominant form of renal cystic disease in humans is autosomal dominant
polycystic kidney disease (ADPKD), which affects approximately 1 in 1,000
individuals and does not become evident until age 50 or more in most individuals

[5;6].

This

disease

often

has

extrarenal

manifestations

cardiovascular system, and gastrointestinal tract [7].

in

the

liver,

Autosomal recessive

polycystic disease (ARPKD) is a more aggressive disorder, which presents late
in fetal development or shortly after birth.

The estimated incidence of this

disease in the human population is 1 in 6,000 to 1 in 55 ,000 live births with a
carrier frequency of approximately 1 :49 [2]. ARPKD is characterized by renal
collecting tubule ectasia, hepatic portal fibrosis, and biliary dysgenesis [8;9].
Clinical complications of the kidney and liver pathology in patients with ARPKD

who survive the neonatal period include systemic hypertension, renal failure,
portal hypertension and ascending cholangitis. A locus for ARPKD has been
localized to chromosome 6 and appears to be the primary locus associated with
ARPKD in humans [10;11]. The gene associated with ARPKD , however, has yet
to be identified .

Mouse models for Polycystic Kidney Disease

Animal models of the various forms of human cystic disease have contributed
greatly to our understanding of the pathogenesis of these kidney disorders [1216]. The recessive cpk (congenital polycystic kidneys) mutation in mice has
been examined in considerable detail [17;18]. Additional spontaneous recessive
mutations in mice - bpk (BALB/c polycystic kidneys), pcy (polycystic kidneys), jck
Uuvenile cystic kidneys), nm/633, and jcpk Uuvenile congenital polycystic kidney)
- have been reported [ 16; 19-22]. The cystic disease that develops in the pcy and
nm/633 models resembles human ADPKD and the cystic disease that develops

in the cpk, bpk, jcpk, and jck models shows similarities to clinical features of
human ARPKD [23-25].

The dual hepatorenal pathology that is a hallmark

feature of human ARPKD has been reported as a feature only in the bpk mouse
[25]. However, in this model, the hepatic pathology is mild or absent dependent
on the genetic background of the animal. Attempts to identify the genes
associated with these mutations have been restricted by the fact that there are
no DNA probes available that are directly associated with the mutant locus in any
of these animals.
Our model of PKO is a recessive mouse mutation that causes a form of
polycystic kidney disease that closely resembles human ARPKD [26].

This

mutation arose by insertional mutagenesis in one line of transgenic mice and is
named orpk (Oak Ridge polycystic kidney).

In contrast to the other animal

models for renal cystic disease, the mutant locus could be cloned using the
exogenously added transgene as a "molecular tag". The orpk mutation arose as
part of a large-scale insertional mutagenesis program at the Oak Ridge National
Laboratory. This line was generated on the FVB/N inbred genetic background by
2

pronuclear microinjection of a transgene construct containing the bacterial
chloramphenicol acetyltransferase gene under the control of a mutated version of
the polyoma early region promoter.

The abnormal phenotype is the result of

disruption of an endogenous gene (Tg737) and is not associated with the
nonexpressed transgene product.

Therefore, the phenotype in the orpk line

occurs only among transgenic homozygotes derived from crosses between
animals hemizygous for the transgene [26]. The mutation is passed from one
generation to another in a simple Mendelian manner and the phenotype in
homozygotes appears to be 100% penetrant since all animals identified by
genotypic analysis as transgenic homozygotes are similarly affected. No mutant
traits are detected in animals heterozygous for the transgene [26].

Phenotype of the orpk mutant animals

The orpk mutant phenotype on the FVB/N genetic background is very severe
with a majority of the affected animals dying within a few weeks after birth
[26;27]. FVB/N orpk mutants have scruffy fur, are severely growth retarded and
also exhibit skeletal abnormalities. The most prominent aspect of the phenotype
involves the invariable development of bilateral polycystic kidney disease and
abnormalities associated with the intrahepatic biliary tract [26;28;29].

Gross

examinations of mutant kidneys revealed that they were slightly enlarged , pale,
and contained numerous cysts with concurrent destruction of the surrounding
parenchyma. The livers are slightly pale with a prominent reticular pattern .
Histologically, the lesions in the kidneys and livers of orpk mutant mice are
remarkably similar to those seen in human ARPKD. The cardinal features of both
the kidney lesion (collecting tubule ectasia) and the liver lesion (biliary dysplasia
3

and/or portal hepatic fibrosis) typical of human ARPKD are a constant finding of
the disease in the mutant animals.

In the kidneys, initial mild , multifocal

microscopic dilation of the proximal tubules is followed rapidly by marked dilation
and cyst formation to the collecting tubules. Lectin profiling was performed on a
total of 12 orpk mutants ranging in age from day 1 to day 28. In newborn animals ,
microcystic lesions were localized to proximal tubules. By postnatal day seven ,
cystic lesions were detected in collecting tubules, and a progressive shift in cyst
localization from the proximal tubules to the collecting ducts was characteristic of
all subsequent developmental stages [26]. This shift from proximal tubules to
collecting duct cysts is similar to that which is observed in the bpk and cpk
mutants [18] . In addition , the advanced lesions in human patients with ARPKD
are located within the collecting tubules and ducts, while proximal tubule cysts
are the prominent features detected at early stages of the disease [18]. The orpk
mutants also have urine with low specific gravity (hyposthenuric) indicating that
the renal concentrating ability is compromised.

Serum creatinine and urea

nitrogen concentration, however, are normal in these animals.
As with the renal lesion , the hepatic abnormality detected in the orpk mutants
is similar to that observed in humans with ARPKD. A prominent feature in both is
an abnormality in the intrahepatic biliary tract involving primarily the bile ducts
and ductules. The liver lesion on the FVB/N genetic background is characterized
by the proliferation of poorly differentiated epithelial cells emanating from the
portal triads and the formation of primitive, dysplastic, tortuous ductules that
expand the portal periportal areas. These cells can ultimately disrupt the limiting
plate, isolate individual hepatocytes, and can give rise to anastomosing tortuous
bile ductules in the end-stage diseased liver [26;28]. Serum concentrations of
4

liver enzymes, specifically alkaline phosphatase (ALP) and alanine transaminase
(ALT) , and bile acids are elevated compared to normal FVB/N mice. The most
marked elevation is in ALP and bile acids supporting the biliary tract origin of the
liver lesion. The mutant animals in the FVB/N genetic background also develop
a pancreatic lesion characterized by pancreatic ductule hyperplasia and
proliferation with fibrosis and acinar cell atrophy. The islet of Langerhans cells
appear unaffected by the lesions, but are less numerous.
To evaluate how genetic background might influence the expressivity of the
orpk phenotype, the mutant locus was made congenic on the C3HeB/FeJLe

inbred genetic background (orpk-C3H line). As in human ARPKD, the pathologic
features of the orpk phenotype include a spectrum of disease with variable
severity in which the primary lesions of the kidneys and liver are expressed to
different degrees. Congenic orpk-C3H mutant mice have a much less severe
phenotype.

This dramatic decrease in severity is evident in first generation

backcross to C3H . Initial experiments clearly show that these animals live much
longer (weeks to months vs. days to weeks), develop renal cysts at a slower rate,
and have a less aggressive liver disease [26]. The significant difference in the
lesions on a different genetic background indicates the presence of important
modifier genes that vary in the FVB/N and C3H genetic backgrounds. This may
also be the case in human ARPKD, in which the severity of the phenotype and
the nature of the liver lesion can be quite variable.

Molecular biology of PKD

Only three genes associated with mutations that cause PKO have been
cloned . Two of these are linked to the most common forms of ADPKD in humans
5

(PKD1 and PKD2) [30;31]. The third gene is associated with the orpk mouse

model for ARPKD [26].

The gene associated with the predominant form of

ARPKD has yet to be cloned; however, the ARPKD locus has been mapped to a
1-cM interval of chromosome 6 in humans [32].

Characterization of the orpk

mutant locus led to the identification of the Tg737 gene that encodes an 824amino acid polypeptide. The interrupted gene at the mutant locus in the orpk line
contains a motif common to several genes involved in cell cycle control. This
motif encodes an internally repeated 32-amino acid sequence referred to as the
tetratricopeptide repeat (TPR). The TPR was first described in lower eukaryotes
as a motif associated with several genes involved in cell cycle control, and
recently, has been identified in proteins that mediate protein-protein interactions
and function in key regulatory pathways [33-35]. The Tg737 protein has recently
been shown to interact with polycystin 1, the protein product of the PKD1 gene
[36] . This finding provides molecular evidence for a common disease pathway
between an animal model for ARPKD and the dominant disease in humans. It
has been theorized that the proteins may exist in a common macromolecular
complex in renal epithelia regulating growth, differentiation, and polarization
[37 ;38]. The Tg737 protein has also been shown to interact with other proteins
involved in epithelial cell polarity, TGF-a/EGF receptor (EGFR) stability and
cellular differentiation [36].

Mechanisms of cystogenesis

Cyst formation in the kidney appears to be the final common pathway for a
large number of genetic and acquired diseases. In the recent years, numerous
general mechanisms and a few specific alterations have been identified that
6

result in cyst generation.

Several studies have focused on the cellular

mechanisms of cyst formation in humans and in animal models of polycystic
kidney diseases. An important finding from these studies is that many features of
the cyst are common to a variety of disorders.

Three factors have been

associated with cystogenesis in these studies; epithelial hyperplasia, secretion ,
and extracellular matrix (ECM) abnormalities.
changes

in

the

expression

of

several

ECM abnormalities include

components,

such

as

matrix

metalloproteinases and cysteine proteinases that regulate active remodeling and
degradation of the ECM [19;39-41]. Tubular secretion is required to maintain the
cyst after development.

Chloride secretion through the cystic fibrosis

transmembrane receptor (CFTR) , persistence of a transient developmental
phenotype in cystic epithelia, and physical properties of mechanical deformation
are all proposed mechanisms that lead to net secretion in cystogenesis (42-44].
In all cases, the cystic structures arise from a localized proliferation of cells in
different sections of the nephron depending on the specific form of the disease
(45-47]. Numerous molecular defects have been associated with the hyperplasia
in tubular epithelial cells including proto-oncogene activation or overexpression,
growth factor and growth factor receptor dysregulation, and abnormalities in
apoptosis (48-51].

Evidence from several studies has shown a direct role of the

EGFR axis in the pathophysiology of PKO (37]. The EGFR has been shown to
be over expressed and mislocalized in the cystic epithelium of human ARPKO
and in several models of PKO, including the orpk mouse mutant (52-54]. These
ongoing studies provide clues to the determination of the pathways and
components responsible for the pathogenesis of cyst formation and may lead to
possible therapeutic applications.
7

Therapeutic applications

There is no specific therapy to ameliorate the progression of PKO in humans.
The understanding of the cellular and molecular events that trigger the formation
of renal cysts and extrarenal lesions in human patients and animal models of
PKO will

aid

in the development of potential treatments.

Taxol,

an

antimicrotubule drug that interferes with the depolymerization of microtubules
and thereby blocks cell division, has been shown to be useful against several
types of malignant neoplasm [39]. Taxol has been shown to be of therapeutic
benefit in the cpk mouse model of PKO, but not in other rodent models of PKO
[55;56] . This difference in therapeutic benefit may be due to the differences in
the mutations at the cellular and molecular level, or due to genetic background
differences that influence the effectiveness of taxol. These factors must be taken
into consideration with any potential therapeutic agent and tested in several
animal models before conclusions can be made towards its benefits in humans.
I have investigated the efficacy of taxol in the orpk mouse model of PKO [57].
This investigation is presented in Chapter II of this manuscript. Dietary factors,
such as protein and fatty acids, have also been studied to determine their effects
on the progression of polycystic kidney disease in animal models [58;59].
Recently, a novel tyrosine kinase inhibitor, EKl-785, has been shown to inhibit
collecting tubule cystic lesions in an organ culture system [60].

The

understanding of the pathophysiology of PKO aids not only in finding potential
therapeutics, but also in the search for modifier genes that have been shown to
vary the phenotypic expression in human PKO and animal models of PKO. The
mapping and cloning of modifier genes that influence the disease process in
PKO, in turn, will aid in finding potential therapeutics.
8

Polygenic Inheritance

Definitions

Characteristics whose phenotypic variation is continuous and determined by
the segregation of multiple loci have often been referred to as polygenic traits
and the inheritance as polygenic. Polygenic traits may be classified as discrete
traits that are measured by a specific outcome such as the development of a
certain disease or characteristic (61]. Discrete traits may represent a threshold
effect that is produced whenever an underlying quantitative variable, influenced
by multiple genes, exceeds a critical threshold . Discrete traits may also be a
pure synthetic effect that requires a simultaneous and joint action of several
mutations. Polygenic traits may also be classified as quantitative traits that are
measured by a continuous variable and are assessed quantitatively such as plant
height, milk production , or blood pressure. The individual loci controlling a
quantitative trait are referred to as polygenes or quantitative trait loci (QTL) (62].
The combined action of individual QTL sets the level of these traits . This form of
polygenic inheritance determines most of the phenotypic characteristics that
distinguish different individuals within a natural population . Quantitative traits can
be described numerically based on the result of an appropriate form of
measurement. Non-genetic factors can also play a role in the continuous
variation in expression of a trait.
matter of chance.

Non-genetic factors are environmental or a

Genetic and non-genetic contributions can be separated

through the analysis and comparison of animals within and between inbred
strains . The analysis of quantitative traits is a subspecialty of genetics called
quantitative genetics, and deals with polygenes or modifier genes that determine
9

the variation in the phenotype. Polygenic inheritance can also refer to multiple
genes that are involved in the variation of a specific disease phenotype.
Phenotypic variation is demonstrated in many animal models when "genetic
background" effects represent the action of modifier genes. Modifier genes
explain , in part, the variability in the phenotypic expression of the same mutation
within a single gene between two different strain backgrounds. The modifying
genes do not have a mutation themselves, but are normal allelic variants that
affect how the mutated gene is expressed or how it causes the disease.
Phenotypic variability can be demonstrated as susceptibility or resistance to a
disease

phenotype,

or

as

a

dramatic

difference

in

the

disease

pathophysiology[61]. Modifier genes are distinct from the disease-causing genes
and may be located on entirely different chromosomes.

Mapping of these

modifier genes can provide tools for understanding the pathophysiology of the
disease itself, and new tools for diagnostic and therapeutic interventions.

Mapping of QTL

Researchers over the past several years have been successful in detecting
and mapping loci affecting polygenic traits in humans, animal models, and
agricultural species (63). Genome-wide QTL analysis was first performed in
plants, but was soon used in mammals.

The initial requirements for QTL

analysis are the availability of inbred strains, a quantitative trait that can be
measured numerically, a difference in expression of the quantitative trait between
the inbred strains chosen , and a method to map the QTL to a chromosomal
location using molecular markers. A QTL analysis can be described in three
stages: detection , map estimation , and fine mapping [63]. Stage 1, the detection
10

stage, can locate the major QTL on chromosomes, determine the number of QTL
segregating, and estimate the additive and dominance effects. Stage 2, the map
estimation stage, localizes the QTL to intervals on the chromosomes. Stages 1
and 2 are performed using a genome wide scan and various statistical methods.
Stage 3, the fine mapping stage, focuses on a single-QTL oriented mapping
within an interval previously identified to contain a modifier locus. Stage 3 has
been difficult to achieve and the experimental designs have not been well tested .
This difficulty has been the reason for the lack of success in positional cloning
and positional candidate gene identification in QTL analysis.
The mapping of modifier genes that control a disease phenotype among
mouse inbred genetic lines can now be performed with greater ease due to
advances in genetic mapping. With the advent of simple sequence repeat DNA
markers (SSLP) that are distributed throughout the entire mouse genome, the
QTL that contribute to a specific phenotype can now be mapped [64;65].
Currently, there are more that 6000 PCR-based highly polymorphic markers
available for the mouse [65]. The markers are spaced along the genomic map to
an average of less than 0.25cM (=500 kb). Between any two inbred strains, an
average of 50% of the markers are polymorphic, making it possible to map to a
resolution of less than 1 cM for any trait.

These markers are utilized in the

genome scan for stages 1 and 2 of the QTL analysis. In stage 1, the frequency
with which a set of genetic markers specific to one of the parental strains is
inherited with the phenotype of interest is measured , and linkage can be
established to the loci involved in modifying that phenotype. This is taken a step
further in stage 2 of the QTL analysis with interval mapping. Interval mapping
uses phenotypic and genetic marker information to estimate the probable
11

genotype and the most likely QTL effect at every point in the genome, by means
of a maximum-likelihood linkage analysis . This analysis is initially done on the
same population as in stage 1, but uses different statistical methods. Specific
software, such as Mapmaker/QTL, has been designed to estimate QTL map
location [66].
In animal models with inbred strains, the most common experimental designs
used to perform the initial genome scan are the intercross (F2) and the
backcross (BC) . The BC matings have proven more efficient in detecting the
major QTL because each BC offspring will have one of only two genotypes at
each locus. There is also less genetic variance in the BC design [63]. However,
if the goal is to know the number of QTL and estimate their additive and
dominance effects, then the F2 design is superior.

The most important

consideration in choosing the inbred parental strains for either design is that they
should show the greatest difference possible in the expression of the quantitative
trait.

After choosing the inbred parental strains, a cross to obtain F1 hybrid

offspring should be performed and the quantitative trait analyzed in this
population. This analysis will aid in determining whether the putative QTL are
dominant, semidominant, or more complex in one strain versus the other. The
mean expression of the F1 population will also aid in determining which parental
Mating F1 animals generates the F2

strain to perform the backcross [67].

progeny. Once the backcross and/or F2 progeny are obtained , they are then
analyzed for expression of the quantitative trait with the same method used for
the F1 and parental strains. These progeny are typed for DNA or molecular
markers that span the genome, such as simple sequence repeat DNA markers.
These molecular markers should be spaced at intervals of 15-25 cM for the
12

detection and interval mapping stages of the analysis [62]. In order to save time
and expense of assaying molecular markers for such a large population of
animals, a modified approach has been developed to detect QTL.

In this

approach , marker analysis is only performed on the progeny from the extreme
tails of the distribution. This is referred to as selective genotyping and only the
progeny with the highest and lowest values for the quantitative trait are
genotyped for the molecular markers in the genome scan . If the allele frequency
at any molecular marker locus differs significantly between the two extreme
subpopulations , then a QTL controlling the quantitative trait of interest may be
located near the marker [62].

The drawbacks of this method are that more

animals must be analyzed for the quantitative phenotype in order to have enough
animals in the distribution extremes.

It is also more difficult to determine

individual QTL effects and to map more that one quantitative trait using this
method [62]. However, if the goal is to detect the major QTL for one quantitative
trait, then the benefits outweigh the penalties when using this method.

Hypothesis and Specific Aims

The hypothesis and specific aims of this project involved different aspects and
methods in understanding the pathophysiology of polycystic kidney disease in
the orpk mouse model.

1. Hypothesis: Agents that block cell division, such as taxol, will decrease the
renal cystogenesis and biliary epithelial proliferation in the orpk mutant animals.
13

Specific Aim: To determine the effect of paclitaxel on cystic kidney and liver
lesions in the orpk mutant line.

2. Hypothesis: Genetic modifiers influence the expression of the orpk phenotype
between different mouse strains.
Specific Aim: To identify the phenotypic variations of the orpk mutation on the
C3H genetic background.

3. Hypothesis:

There are several modifier genes varying the severity of the

kidney and liver lesions in the orpk mutants between the FVB/N and C3H genetic
backgrounds.
Specific Aim: To determine the chromosomal location of the modifier genes that
vary the phenotypic expression of orpk between the FVB/N and C3H genetic
backgrounds.
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II. EFFICACY OF TAXOL IN THE ORPK MOUSE MODEL
OF POLYCYSTIC KIDNEY DISEASE

Introduction

There is no specific therapy to ameliorate the progression of ARPKO in
humans. Taxol, an antimicrotubule drug that interferes with the depolymerization
of microtubules and thereby blocks cell division, has been shown to be useful
against several types of malignant neoplasm [39] . A previous study showed that
taxol slowed the progression of renal cyst formation in the cpk mouse model of
PKO [55]. Most notably, the treated cpk animals had an increased survival rate
over nontreated animals. To determine whether this is a generalized effect of
taxol that is applicable to other forms of PKO, we tested whether mouse mutants
other than cpk animals also respond to this drug.

Here we demonstrate that

treatment with taxol has no effect on the development of renal cysts in the orpk
mutant line. Moreover, careful analysis of the livers in the orpk mutants revealed
that taxol also has no obvious beneficial effect on the liver lesions that develop in
these animals.

Materials and Methods

Animals

Three treatment groups were established, each consisting of 10 orpk mutant
mice and 10 wild-type control mice. Group 1 received taxol in dimethyl sulfoxide
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(DMSO) at 1O µg/g body weight (BWt) weekly via an intraperitoneal injection.
Group 2 received only DMSO and Group 3 received only PBS , both at equal
volume/g BWt. and dosing interval as Group 1. All treatments began at 7 days of
age. The mice were maintained with their parents until they were weaned at 24
days of age and genotyped for the transgene using a PCR based protocol. All
mice were weighed twice weekly and sacrificed when near death or by 50 days
of age .

Serum and urine analysis

Serum

concentrations

of

alkaline

phosphatase

(ALP),

and

alanine

transaminase (ALT) were measured to assess liver damage in three mutant mice
of Group 1, three mutant mice of Group 2, two mutant mice of Group 3 and all
control mice. Urine osmolality was measured and the urine osmolality to serum
osmolality (Uosm:Sosm) ratio was calculated to assess renal concentrating
ability in three mutant mice of Group 1, three mutant mice of Group 2, two mutant
mice of Group 3, and all control mice. A complete blood count was performed on
all control animals.

Serum samples were analyzed by an Abbott spectrum

chemistry analyzer, and serum and urine osmolality were measured by a Wescor
vapor pressure osmometer.

Light microscopy

For histological analysis, kidneys and livers were obtained from mutant and
control animals at necropsy. The tissue was fixed in 10% buffered formalin for
24-48 hours and embedded in paraffin . Sections of 5µm were mounted on glass
slides and stained with hematoxylin and eosin.
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Determination of cystic index
Cyst localization was studied by segment-specific lectin binding using Dolichos
biflorus as a marker specific for collecting tubules and Lotus tetragonolobus as a

marker specific for proximal tubules. Processing and immunostaining of tissues
was performed as previously described using a post-embedding technique
specifically developed for immunolocalization of antigens and lectins in plastic
sections [68] . Following routine histological preparation, 6-10 regularly spaced ,
3µm sections of kidneys were graded for cyst formation using an eyepiece
micrometer on a scale of O (no observable cysts) through 4 (multiple cysts larger
than 0.2 mm). The cystic index was then calculated as the mean of individual cyst
scores.

lmmunohistological localization of the Epidermal Growth Factor Receptor
(EGFR)
The cellular localization of the EGFR was determined by immunohistological
staining of mutant kidney sections with monoclonal EGFR antibodies, F-4 (Sigma.
St. Louis, MO, USA) or HB 8506 (American Type Culture Collection, Rockville, MD,
USA) or Rabbit antiserum, RK-2 as described [53;68;69].

Statistical analysis
Utilization of 10 animals in each treatment group was based on the following
power analysis: assuming treatment would double length of survival, at an alpha
level of 0.01, the power of this study is 0.94, and at an alpha level of 0.05, the
power of this study is 0.97 (Solo Power Analysis, BMDP Statistical Software, Inc,
Los Angeles, CA). An estimate of the mean (SEM) biweekly body weight, age at
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death, ALP and ALT values, and serum osmolality to urine osmolality ratio values
for control and mutant animals of each treatment group were made. A paired

t-

test was used to determine differences between treatment groups for these
values. A paired t-test was used to determine differences between treatment
groups for cystic index. Statistical significance was considered at p<0.05.

Results

We tested whether the effects of taxol on renal cystogenesis in the cpk mouse
model of PKD can be extended to other PKD models, and additionally whether it
has an effect on the liver lesion that accompanies renal cysts in ARPKD
[17;25;70]. For this purpose we chose to use the orpk line, which is a mouse
mutation that develops kidney and biliary lesions which parallel those of human
patients with ARPKD [26] . We chose to use a similar dose of taxol (10 µg/g BWt.
by intraperitoneal injection weekly) that was reported to be nontoxic to the
animals and proved effective in decreasing the progression of renal cyst
formation in cpk mice [55].
We maintained the orpk mutation on the FVB/N strain , since on this genetic
background the phenotype is the most severe. Orpk homozygous mutants are
noticeably growth retarded , and die within a few weeks after birth [26]. Since the
orpk mutation has been characterized at the molecular level, we were able to

genotype the individual animals to verify that they were homozygous for the trait.
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To evaluate the effect of the taxol treatment on body weight and survival,
values for life span were determined for mice of each treatment group (Fig. 1),
and all animals were weighed twice weekly for control and mutant mice in each
group (Fig. 2). There was no significant difference in mean life span between the
mutant mice in each treatment group. The mutant mice in each group died or
were sacrificed due to illness by 28 days of age except for one animal in the
DMSO treatment group, which lived to 45 days of age. All control mice lived for
the full 50 days with no adverse effects from the taxol or DMSO treatments.
There was no significant difference in the weight curves of the control mice of
treatment Group 1 and 2, indicating that taxol had no effect on growth in these
animals.
To evaluate kidney tubule function, we calculated the Uosm:Sosm ratio ,
which is the parameter that best correlates with the decreased ability of the
kidney to function as the cystic disease progresses[27] . We found no significant
difference between the treatment groups with respect to the Uosm:Sosm ratio
(Fig. 3) .

The latter result indicated that the compromised renal concentrating

ability was not corrected by treatment with taxol. Since the orpk mutant mice
have normal serum creatinine and

urea nitrogen concentrations, these

parameters were not measured.
Histological examination of the kidney lesions showed no difference in the
severity between the treatment groups (Fig . 4) , and morphometric analysis of the
renal cysts confirmed that there was no difference in the progression of the renal
lesions between the treatment groups (Table 1). Lectin staining of the
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Figure 1. Mean age at death for ten orpk mutant mice in each treatment group.
Mean values are presented within each column and bars indicate the standard
deviation of the mean. Source: Sommardahl CS , Woychik RP , Sweeney WE,
Avner ED , Wilkinson JE: Efficacy of taxol in the orpk model of polycystic kidney
disease. Pediatr.Nephrol. 11 :728-733, 1997.
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Mean body weight curves during the study for 10 wild-type (W7)

control animals in the taxol- and OM SO-treated groups and the 10 mutant
animals in the taxol-, DMSO-, and PBS-treated groups.

Source: Sommardahl

CS, Woychik RP, Sweeney WE, Avner ED, Wilkinson JE: Efficacy of taxol in the
orpk model of polycystic kidney disease. Pediatr.Nephrol. 11 :728-733 , 1997.
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Mean urine to serum osmolality ratio for orpk mutant mice in each

treatment group. Mean values are presented within the column and bars indicate
the standard deviation of the mean. (Taxol-treated orpk mutants n = 3, DMSOtreated orpk mutants n = 3, PBS-treated orpk mutants n= 2) .

Source:

Sommardahl CS, Woychik RP, Sweeney WE, Avner ED, Wilkinson JE: Efficacy
of taxol in the orpk model of polycystic kidney disease. Pediatr.Nephrol. 11 :728733, 1997.
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Figure 4. Histological sections of kidneys (hematoxylin and eosin , X10) from 28-

35 day old orpk mutant mice from each treatment group showing the
development of renal cysts. Kidney section from (A) taxol treated orpk mutant,
(B) DMSO treated orpk mutant, and (C) PBS treated orpk mutant showing no

difference in the severity of the renal cystic lesions between each treatment
group.

Source: Sommardahl CS , Woychik RP, Sweeney WE, Avner ED,

Wilkinson JE: Efficacy of taxol in the orpk model of polycystic kidney disease.
Pediatr.Nephrol. 11 :728-733, 1997.
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Table 1.

Cystic index for untreated mice, and taxol-treated and dimethyl

sulfoxide (DMSO)-treated control and orpk mutant mice calculated as the mean
of the individual cyst scores. Source: Sommardahl CS, Woychik RP, Sweeney
WE, Avner ED, Wilkinson JE: Efficacy of taxol in the orpk model of polycystic
kidney disease. Pediatr.Nephrol. 11 :728-733, 1997.

Cystic Index

Treatment Group

Untreated controls

0

Taxol treated controls

0

DMSO treated controls

0

Untreated mutants

4.0(0.50)

Taxol treated mutants

4.0(0.50)

DMSO treated mutants

4.25(0.57)
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kidney sections also showed no difference in the progressive shift in cyst
localization between the treatment groups, indicating that taxol had no effect on
cystogenesis at any stage of the disease.
We also determined whether taxol has any effect on the development of the
hepatic lesions that develop in the orpk mutants. In the FVB/N genetic
background , the liver lesion in the orpk mutant is normally characterized by
proliferation of poorly differentiated epithelial cells emanating from the portal
triads that form primitive, dysplastic ductules that expand the periportal areas
[26) .

Histological examination of the livers of orpk mutant mice showed no

differences in the lesions between the treatment groups (Fig . 5) .

We also

evaluated the serum concentration of ALP and ALT, which are normally elevated
in response to liver damage.

Serum concentrations of ALP were markedly

elevated and serum concentrations of ALT were mildly elevated in orpk mutant
mice, and it did not appear that taxol had any affect on decreasing either
parameter (Fig. 6). Serum concentrations of ALP and ALT in the control mice
were within normal limits for FVB/N mice.
Finally, we determined whether taxol treatment has any effect on the targeting
of the EGFR within the epithelial cells lining the renal cysts. Recent studies have
focused on the role of TGF-a and EGF along with their common receptor, EGFR,
in the epithelial hyperplasia in the collecting tubules and ducts.

The EGFR,

which is normally present only on the basolateral surface, is mistargeted to both
the basolateral and apical surfaces of cystic collecting duct epithelium in PKO
[71 -73).

The intracellular microtubular network plays a role in receptor

localization to membranes and inhibition of this function by taxol may disrupt the
mislocalization seen in the cysts.

Our results showed no difference in the
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Figure 5. Histological sections of liver (hematoxylin and eosin, X10) from 28-35
day old orpk mutant mice from each treatment group showing the biliary
hyperplasia/dysplasia in the periportal regions .

Liver sections from (A) taxol

treated orpk mutant, (8) DMSO treated orpk mutant, and (C) PBS treated orpk
mutant showing no difference in the liver lesions between each group.

Source:

Sommardahl CS, Woychik RP, Sweeney WE, Avner ED, Wilkinson JE: Efficacy
of taxol in the orpk model of polycystic kidney disease. Pediatr.Nephrol. 11 :728733 , 1997.
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Figure 6. Mean values for serum concentrations of alkaline phosphatase (ALP)

and alanine transaminase (ALT) for orpk mutant mice in each treatment group.
Mean values are presented at the top of each column and bars indicate the
standard deviation of the mean. (Taxol-treated orpk mutants n = 3, DMSOtreated orpk mutants n

= 3,

PBS-treated orpk mutants n

= 2)

Source:

Sommardahl CS, Woychik RP, Sweeney WE, Avner ED, Wilkinson JE: Efficacy
of taxol in the orpk model of polycystic kidney disease. Pediatr.Nephrol. 11 :728733, 1997.
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mislocalization of the EGFR with taxol treatment (Fig. 7). This result indicates
that the mislocalization occurs independent of microtubular function.

Discussion

The availability of a drug that has the potential to control the formation of renal
cysts would revolutionize the treatment of PKO.

In experiments with the cpk

mouse model for PKO, Woo et al previously determined that taxol at a dose of
150 µg injected into an affected mouse on a weekly basis decreased the
progression of renal cystogenesis and had only minimal toxicity to the animal
[55] . It remained to be determined whether taxol treatment is applicable to other
heritable forms of PKO that are initiated by different mutations. This is important
since the predominant forms of human PKO are not initiated by the same genetic
defect that triggers the disease in the cpk mouse mutant [10;17].

Here we

describe experiments with the orpk mouse mutation, which causes a form of
recessive PKO that closely resembles the disease progression in humans with
ARPKO [26]. Taxol has no effect on the disease in the orpk mutants when given
at the dose that was effective in the cpk model.

In all evaluated parameters,

including body weight, survival, and hepatorenal histology, there was no
improvement with taxol treatment. Therefore, we conclude that taxol treatment is
not effective in this particular model of PKO.
This report tests taxol under treatment conditions determined to be effective in
another murine model of PKO [55]. The dose utilized (1 0µg/g) has been shown
to have beneficial effects in the cpk mutant in unpublished studies by ourselves
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Figure 7. Histological sections of a kidney (132X) showing the immunohistological
localization of the EGFR in the taxol treated orpk mutant with the EGFR localization
to both the apical (solid arrow) and basolateral surfaces in cystic epithelium, but only
to the basolateral surface in noncystic tubules (open arrow).
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and Woo et al. (personal communication). The orpk mutation is on the FVB/N
genetic background , while the cpk mutation is on a C57BU6 genetic background ,
raising the possibility that genetic background may have an influence on the
effectiveness of taxol as a therapeutic agent. Genetic background can influence
the expressivity of genetic traits. In fact, modifier genes on chromosome 1 and
chromosome 10 for the jck mouse model for AO PKO have already been mapped
[74]. These modifying loci mediate the severity of PKO in the jck mouse.

Thus,

some of the variability in PKO expressivity in the human population may be
accounted for by genetic background.

Additional experiments with the orpk

mutation on the C57BU6 and other backgrounds will address this possibility.
Provided that genetic background and dose are not contributing factors in the
lack of effectiveness of taxol, it is possible that the cpk mutation is fundamentally
different than the orpk mutation at the molecular and cellular level. Although both
forms of PKO exhibit a localized proliferation of epithelial cells and mistargeting
of the EGFR [27;71 ;72], the initiating event is different since the two mutations
map to different chromosomes [17;26]. Also, the disease conditions have a
different

progression

of the

renal

pathology,

and

different

multiorgan

histopathology. In the cpk mutant mouse, the collecting duct cysts progress to
cause gross enlargement of the kidneys, and the mice die of uremia within 4-5
weeks of age [17].

In contrast, the collecting duct cysts in the orpk mutant mice

rarely cause enlargement of the kidneys and the mice do not develop uremia
[26) .

In the cpk model, the microtubule network may play a role in the

cystogenesis since taxol interferes specifically with microtubule functions [39].
This may not be the case for the orpk mutant line.

For this reason it will be

important to test other mutants to determine whether they respond to taxol
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treatment. Of particular interest will be targeted mutants in the mouse genes for
ADPKD once these mouse strains become available.
Taxol also failed to alter the proliferation and dedifferentiation of the biliary
ductules within the livers of orpk mutant mice.

These abnormalities in the

intrahepatic biliary tract are a constant and prominent feature of both orpk mutant
mice and humans with ARPKD, but not cpk mice. The liver lesions become
progressively more severe with age in ARPKD patients, and portal hypertension ,
hepatosplenomegaly, bleeding esophageal varices, and ascending cholangitis
are common complications [70;75] . Therefore, even if a drug is not effective
against the renal cysts, it may still have potential therapeutic value if it is active in
ameliorating the liver lesion. This is not the case with taxol in this study.
The development of pharmaceuticals that are effective in the treatment of
PKO will undoubtedly follow from a better understanding of the cellular and
molecular events that trigger the formation of renal cysts. Knowing specifically
which molecules are not functioning properly can be useful for the development
of designer drugs that target a specific defect. For example, we recently have
bred animals carrying the orpk mutation to waved-2 mice that harbor a mutation
in the EGFR that causes a decrease to about 10% of the normal level of tyrosine
kinase activity [54). Double mutant (orpklwaved-2) animals show a significant
impairment in renal cyst formation revealing an in vivo role for the EGFR pathway
in renal cyst formation in PKO. In this case, it may be possible to identify a
compound that will specifically block the tyrosine kinase activity of the
mistargeted EGFR on the apical surface of the collecting duct. These and other
experiments should provide new insights into the development of unique
therapies for human PKO.
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Ill. PHENOTYPIC VARIATIONS OF THE ORPK
MUTATION ON THE C3H GENETIC BACKGROUND

Introduction

In both AOPKO and ARPKO in humans, the variable expressivity of the
phenotype with respect to disease progression and extrarenal manifestations is
remarkable.

This variability is in part due to genetic heterogeneity due to

mutations in distinct genes giving rise to PKO. However, marked variability in
clinical disease has been reported between kindred that probably have the same
mutation predisposing them to

PKO indicating that other genetic and

environmental factors are likely to affect the manifestation of the phenotype [76].
Effects of genetic background have also been reported in mouse models of PKO
in respect to disease severity [26;74;77;78].
To better evaluate how genetic background might influence the expressivity of
the orpk phenotype, we have bred the orpk-FVB/N (orpk-F) animals onto the
C3HeB/FeJLe background. We have made the mutant locus congenic on the
C3HeB/FeJLe background (orpk-C3H line). Congenic orpk-C3H (orpk-C) mutant
mice have a much less severe phenotype. Initial experiments clearly showed
that these animals live much longer (weeks to months vs. days to weeks),
develop renal cysts at a slower rate, and have a less aggressive liver lesion[26].
Here, I describe the major phenotypic variations of the orpk mutation on the
FVB/N and C3HeB/FEJLe genetic backgrounds.
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Materials and Methods

Mice

The orpk-F mouse model was generated as part of a large-scale insertional
mutagenesis program at the Oak Ridge National Laboratory. Transgenic mice
were generated on the FVB/N genetic background following standard pronuclear
injection protocols [79].

The transgene was made congenic on the

C3HeB/FEJLe (C3H) genetic background by breeding orpk-F mice hemizygous
for the orpk locus to wild-type C3H animals. The hemizygous offspring were
subsequently backcrossed to wild-type C3H animals and this was continued for 9
generations. All animals were handled in accordance with National Institute of
Health guidelines.

Genotyping of animals

Genotyping of animals f<?r the orpk locus was performed by polymerase chain
reaction (PCR) analysis on DNA isolated from tail biopsies using previously
described conditions [28]. The sequence of the primers for orpk genotyping are
RW450-5' ATGCACAAAGTTAGCTCTGC 3',
RW451-5' GGATCCAGCAATACCTCTCC 3', and
RW452-5'CAGGCCATGGATCCAACTCT 3'. RW450 is located in the genomic
sequence just 5' to where the transgene integration occurred in the mutant
animals and will thus serve as a forward primer for both mutant and wild type
Tg737 alleles. RW451 is a reverse primer located at the 5' end of the transgene
and will produce a 340-bp fragment corresponding to the mutant allele. RW452
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is a reverse primer generated to a genomic sequence that is deleted in orpk
mutant animals as a result of the transgene integration and produces a 270-bp
PCR fragment corresponding to the wild-type allele.

Histological analysis of renal, hepatic, and pancreatic tissues

The kidney, liver, and pancreas from orpk-C and orpk-F mutant animals were
fixed in 10% buffered formalin and then processed by paraffin wax embedding .
Sections (5 to 8 µm) were cut and attached to glass slides and were then
dewaxed and stained with trichrome and/or counterstained with hematoxylin and
eosin.

Serum and urine analysis

Blood was collected from metafane-anesthetized mutant animals by retroorbital sinus puncture or at necropsy via cardiac puncture. Urine was collected
from mutant animals by a free-catch method on cellophane.

Serum was

separated in microtainer tubes (Becton Dickinson , Rutherford , NJ) following the
manufacturer's instructions.

Serum concentrations of alkaline phosphatase

(ALP) and bile acids were measured to assess liver damage and function
respectively. Urine specific gravity and urine osmolality were measured, and the
urine osmolality to serum osmolality ratio was calculated to assess renal
concentrating ability. An automated biochemical analyzer (Spectrum, Irving , TX)
analyzed serum samples.

Serum and urine osmolality were measured using a

vapor pressure osmometer (Wescor, Logan , UT).
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Morphometric analysis

Hematoxylin and eosin stained histological sections of kidney from 10 orpk-F
and 10 orpk-C mice were used for morphometric analysis of the kidney lesion.
The percentage of the total area of kidney that is cystic was measured using a
computerized imaging system connected to a videoscope (Bioquant, Nashville,
TN). A cross-section and a longitudinal section of kidney were measured from
each animal and the cystic percentages of these two sections were summed to
obtain the total percentage of cystic kidney.

Results

Kidney

In the kidneys of the orpk-F mutants, initial mild, multifocal microscopic
dilation of the proximal tubules is followed rapidly by marked dilation and cyst
By postnatal day seven, cystic lesions

formation to the collecting tubules [26].

were detected in collecting tubules, and a progressive shift in cyst localization
from the proximal tubules to the collecting ducts was characteristic of all
subsequent developmental stages [26].

The kidney lesions are morphologically

similar in the orpk-C mutant mice, but they develop renal cysts at a slower rate
and have fewer cysts at all stages of cyst development (Fig . 8) .

Proximal

tubular cysts were not detected until 15-20 days of age. The progression shift in
cyst localization from proximal tubules to collecting ducts occurs and the renal
cysts are all localized to collecting tubules by 70 days of age. Morphometric
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Figure 8. Histological sections of the kidneys (hematoxylin and eosin , X10) from

a 20 day old orpk-F mutant (A), and a 28 day old orpk-C mutant (B). In contrast
to the renal histology in the orpk-C mutants, large renal cysts are detectable in
the orpk-F mutants at this age.
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analysis of kidney sections from 20-30 day old orpk-F and orpk-C mutant animals
showed a marked difference in the percentage of the total kidney area that was
cystic. The mean values were 18.03 % and 0.58 % for the orpk-F and orpk-C
mutants, respectively.

Liver

The liver lesions in the orpk-F mutant animals are characterized by the
proliferation of poorly differentiated epithelial cells emanating from the portal
triads and form primitive, dysplastic, tortuous ductules that expand the portal
periportal areas (Fig . 9A) . These cells can ultimately disrupt the limiting plate,
isolate individual hepatocytes, and can give rise to anastomosing tortuous bile
ductules in the end-stage diseased liver [26;28].

The liver abnormality is first

observed in orpk-F mutants at postnatal day 5 with an excess of bile ductular
structures and proliferation of nonparenchymal epithelial cells (oval cells)
centered on the portal triad area. The proliferating oval cells expand the portal
triad area and move outward from the portal triad into the periportal area as the
mice mature [28]. There is very little portal fibrosis observed within these lesions.
The liver lesions in the orpk-C mutant animals are not as diffuse and are
characterized by multifocal biliary hyperplasia, dysplasia, and portal fibrosis
isolated to the portal triad regions (Fig. 98).
resemble the liver lesion in human ARPKD.

These features more closely
The most striking feature of the

orpk-C phenotype is the formation of excess biliary ductules secondary to biliary

hyperplasia that expand the portal triad area. The lesions are seen in the first
week postnatal and begin as mild biliary hyperplasia and dysplastic duct
formation . As the mice mature, the biliary ducts continue to proliferate forming
40

Figure 9. Histological sections of the liver (hematoxylin and eosin, X10) from a

24 day old orpk-F mutant (A), and a 20 day old orpk-C mutant (B) . The liver
lesion is more extensive in the orpk-F mutants with hyperplasia of oval cells
(arrows in A) expanding the portal triad area into the periportal space.

The liver

lesions in the orpk-C mutant animals are not as diffuse and are characterized by
multifocal biliary hyperplasia, dysplasia, and portal fibrosis isolated to the portal
triad regions (arrows in B).
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multifocal areas of biliary hyperplasia and dysplasia centered on the periportal
area . There is a decrease in the presence of the proliferating nonparenchymal
cells seen in the orpk-F mutant animals. However, there is a greater degree of
fibrosis present surrounding the dysplastic biliary ductules.

Pancreas

The pancreatic lesion in the orpk-F mutant animals begins as pancreatic
ductular hyperplasia and dysplasia that disrupts the normal acinar cell
architecture.

The proliferating ducts become the prominent features of the

pancreas as the acinar cells disappear. This disappearance of the acinar cells is
felt to be secondary to apoptosis, since there is no evidence of necrosis or
inflammation within the lesions. The islets of Langerhans are not affected by the
ductular hyperplasia, although there appears to be fewer present in the sections
examined .

As the orpk-F matures, the normal exocrine pancreatic tissue

disappears, leaving scattered islets of Langerhans within the mesenteric adipose
tissue. This pancreatic lesion is highly variable between orpk-F mutant animals
and the degree of severity seems to correlate with the survival of the mutants.
The mutants that live past weaning have more exocrine pancreatic tissue present
than those that die early in life.

The pancreatic lesion in the orpk-C mutant

animals also begins as a pancreatic ductular hyperplasia and dysplasia that
expands into the normal acinar cell tissue. The proliferating ductules progress to
form cyst structures that enlarge to form space-occupying cysts within the
abdomen (Fig . 10). The developing cysts can be seen microscopically as early
as 15-20 days of age and occur prominently in the cranial arm of the pancreas
that lies near the greater curvature of the stomach
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Figure 10. Gross appearance of a large pancreatic cyst (arrow) occupying the

cranial abdominal area in a 90 day old orpk-C mutant.
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and the spleen.

The cysts are lined by a cuboidal epithelium that resembles

normal pancreatic ductular epithelium and are fluid filled .

The dysplastic

pancreatic ductules and cysts are surrounded by extensive fibrosis and the
normal acinar cell structures are reduced (Fig. 11 ). The islets of Langerhans are
not affected by the proliferating ductules, but are crowded by the expanding
cysts, as is the rest of the normal pancreatic architecture.

Serum and Urine Analysis

The orpk-F mutants have urine with low specific gravity and low urine: serum
osmolality ratio indicating that the renal concentrating ability is compromised .
Serum creatinine and urea nitrogen concentration, however, are normal in these
animals. The orpk-C mutants retain their renal concentrating ability as measured
by urine specific gravity and urine:serum osmolality (osm) ratio until late in the
disease

progression

(Fig .

12).

Serum

creatinine

and

urea

nitrogen

concentrations are also within normal limits in these animals.
Serum concentration of alkaline phosphatase (ALP} , a liver enzyme used as a
marker of biliary abnormalities, and serum concentration of bile acids are
markedly elevated in orpk-F mutants supporting the biliary origin of the lesions.
Serum concentrations of ALP and bile acids in the orpk-C mutant animals are
only mildly elevated as compared to orpk-F mutants (Fig. 13).
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Figure 11. Histological section of the pancreas (hematoxylin and eosin, X10)
from a 24 day old orpk-C mutant showing the dysplastic pancreatic ductules
and cysts (large arrow) surrounded by extensive fibrosis (small arrow).
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Figure 12. Renal concentrating ability was analyzed by comparing the mean

urine osmolality:serum osmolality (urine osm:serum osm) ratio in the orpk-F
mutants and the orpk-C mutants demonstrating a loss of concentrating ability in
the orpk-F mutants. Mean values are presented within each column and bars
indicate the standard deviation of the mean.
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column and bars indicate the standard deviation of the mean.
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Discussion

The major phenotypic variations of the orpk mutation on the FVB/N and C3H
genetic backgrounds have been described. As in human ARPKD, the pathologic
features of the orpk phenotype include a spectrum of disease with variable
severity in which the primary lesions of the kidneys and liver are expressed to
different degrees.

In the FVB/N genetic background, the phenotype is very

severe in the kidney, liver, and pancreatic lesions and the majority of the animals
die within several weeks after birth. Congenic orpk-C mutant mice have a much
less severe phenotype and survive to several months of age. This dramatic
decrease in severity is evident in first generation backcross to C3H. The most
striking variation in severity was in the kidney phenotype. The kidney lesions are
morphologically similar in both genetic backgrounds, but the orpk-C mutants
develop renal cysts at a slower rate and have fewer cysts at all stages of cyst
development.

The progressive shift from proximal tubular dilations to collecting

tubule cysts is evident in both genetic backgrounds, however, the disease
progression is much more rapid in the orpk-F mutants. The kidneys of orpk-C
mutants do not show tubular dilations or cysts until they are 2-3 weeks of age.
The renal cysts are not localized to collecting tubules until they are 2-3 months of
age and end-stage renal disease is not evident until much later. These animals
also retain their renal concentrating ability as measured by urine specific gravity
and urine: serum osmolality ratio until late in the disease progression .
As with the renal lesion, the hepatic abnormality detected in both genetic
backgrounds is similar to some degree, but the orpk-F mutants develop a much
more severe lesion, which progresses rapidly. The common feature of the liver
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phenotype in both genetic backgrounds is the biliary ductular hyperplasia and
formation of numerous bile ductule- like structures. The orpk-F mutants also
have a proliferation of an immature epithelial cell characterized as an oval cell.
This proliferation expands the lesion from the portal triad into the periportal area
invading the hepatic parenchyma. The proliferating oval cells eventually formbridging lesions between portal triads causing a diffuse hepatic lesion.
Conversely, the lesion in the orpk-C mutants remains confined to the portal triads
with the formation of an excess of biliary ductular structures that expands the
portal area as the lesions progress. There is a marked reduction to an absence
of the proliferating oval cells in the orpk-C mutants, but there is a greater degree
of fibrosis within the liver lesions. This difference in the cell types present in the
lesions suggests a variation in the differentiation signals or response to these
signals between the two genetic backgrounds when the orpk mutation is present.
The liver lesions in the C3H background are characterized by multifocal biliary
hyperplasia, dysplasia, and portal fibrosis isolated to the portal triad regions.
These features more closely resemble the liver lesion in human ARPKD . The
elevation in serum ALP and bile acid concentrations seen in the orpk-F mutants
may simply be a reflection of the severity of the liver lesion in these animals
compared to the orpk-C mutants. The elevated ALP may also be due to the
proliferation of the oval cells that occurs in the orpk-F mutants.
The pancreatic lesion has not previously been described in the orpk-F
mutants, and is also more severe in these animals than in the orpk-C mutants.
The loss of normal exocrine pancreatic acinar tissue in the orpk-F mutants
begins shortly after birth and is a major factor in their runted appearance and
poor growth, since the exocrine pancreas is a key player in the digestion of
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nutrients.

The loss of acinar tissue in the orpk-C mutants is much slower

occurring over several weeks, however, they develop pancreatic ductular cysts
that grow into large cysts within the cranial abdominal cavity. Pancreatic cysts
are uncommon in human ARPKD patients but have been reported to occur in
10% of patients with ADPKD [6]. Pancreatic cystic disease has recently been
reported in a mouse model of polycystic kidney disease with a targeted mutation
that disrupts the mouse homologue of PKD1, the major gene associated with
ARPKD. The mice homozygous for this mutation develop pancreatic ductual
dilatation during gestation and cystic enlargement of the pancreas during the
perinatal period [80].

The similarity of the lesions in these two mouse models

with regard to the pancreatic lesion suggests a common pathogenesis that leads
to abnormal pancreatic tubular epithelial development and warrants further
investigation.
The significant difference in the lesions on a different genetic background
suggests the presence of important modifier genes that vary in the FVB/N and
C3H genetic backgrounds. This may be also the case in human ARPKD and
ADPKD , in which the severity of the phenotype and the nature of the extrarenal
lesions can be quite variable. Based on the analysis of these phenotypes, the
modifier genes appear to be dominant in the C3H background since this dramatic
decrease in severity is evident in first generation backcross to C3H . The orpk-C
mutants also provide a model of the extrarenal lesions of ARPKD and ADPKD
that can be studied to better understand the development of the epithelial
proliferation and dysgenesis in the liver and pancreas.
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IV. CHROMOSOMAL LOCALIZATION OF THE MODIFIER
GENES THAT INFLUENCE THE PHENOTYPIC
EXPRESSION OF ORPK IN THE FVB/N AND
C3HeB/FEJLe GENETIC BACKGROUNDS
Introduction

Significant differences in the lesions when the orpk mutation is on a different
genetic background suggest the presence of important modifier genes that vary
in the FVB/N and C3H genetic backgrounds. Effects of genetic background have
also been reported in mouse models of PKO with respect to disease severity
[20;7 4;78].

Potential modifiers affecting the severity of the cystic progression

have been detected in several of these mouse models [74;81-84].

In the pcy

mouse, whole genomic quantitative trait loci mapping identified two loci that
modulated PKO progression based on kidney:body weight ratio. These loci were
on chromosome 4 and 16 [84] . Using the same quantitative trait character, two
loci on chromosome 4 were detected in a genome scan in the cpk mouse model
[83]. Two regions (one on chromosome 10 and one on chromosome 1) were
found to be associated with inheritance of a more severe PKO phenotype in the
jck mouse model using kidney weight as the quantitative character in a genome

scan [81].

Recently, a new mouse mutation, kat 2J, on chromosome 8, that

causes late-onset PKO and anemia has been identified.

Genome scans

revealed two loci that affect the severity of PKO based on kidney weight, one on
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chromosome 1 and another on chromosome 19 [85]. At this time, these modifier
loci have not been finely mapped nor have candidate genes been identified . My
aim in this study was to map the chromosomal location of the modifier genes that
affect the severity of disease in the orpk mouse between the FVB/N and C3H
genetic backgrounds .

Microsatellite DNA Variants between the FVB/N and C3H Mouse
Strains

The FVB/N strain originally arose from an outbred colony of N:GP Swiss mice
at the National Institute of Health (NIH).

They are commonly used in the

generation of transgenic animals, because the male pronucleus is easily
visualized and they have good reproductive performance [86].

The use of

FVB/N for genetic mapping studies is limited by the lack of information regarding
DNA variant alleles between FVB/N and other inbred mouse strains. Therefore,
the first step in my QTL analysis was to identify SSLP or microsatellite markers
spread throughout the genome that are polymorphic between the FVB/N and
C3HeB/FeJLe (C3H) strains.

In a collaborative study with Dr. David Beier's

laboratory at the Harvard Medical School , Boston , we have screened over 300
microsatellite markers distributed throughout the genome for polymorphism
between FVB/N , C57BU6J (BU6) , and C3H mouse strains and these results
have been published [87].
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Materials and methods

FVB/N , C3H, and BU6 were obtained from The Jackson Laboratory and the
Oak Ridge National Laboratory. Genomic DNA was prepared from mouse tails
and amplified by PCR with primers for microsatellite markers developed at the
Whitehead Institute/MIT center for Genome Research and obtained from
Research Genetics (Huntsville, Ala) .

PCR was carried out in either of two

protocols. Protocol 1 was as follows : an aliquot of 100 ng of genomic DNA was
amplified in 20 µI PCR reaction containing 10 mM Tris-HCL (pH 8.0), 50 mM
KCL, 1 µM of each primer, 2.0 mM MgClz, 250 µMeach dNTP, and 2.5 units of
Taq polymerase (Boehringer-Mannheim, Ind .). PCR reactions were overlaid with
20 µI of mineral oil (Sigma, Mo.) and amplified in a thermal cycler (Hybaid) as
follows: 1 cycle 95°C for 5 min, 60°C for 2 min, and 72°C for 3 min; 30 cycles
95°C for 1_min, 60°C for 2 min, and 72°C for 3 min. A final elongation step at
72°C for 10 min followed.

Protocol 2 was as follows:

an aliquot of 20 ng of

genomic DNA was amplified in 20 µI PCR reaction containing 22 mM Tris-HCI
(pH 8.4), 55 mM KCI, 0.66 µM of each primer, 1.65 mM MgCl 2 , 880 µM dNTPs,
and 0.44 units of Taq polymerase (Gibco-BRL). PCR reactions were amplified in
a thermal cycler (MJ Research) as follows: 1 cycle 95°C for 5 min; 30 cycles of
95°C for 45 s, 45-55°C for 45 s, and 72°C for 2 min and 30 s. A final elongation
step at 72°C for 5 min followed . PCR products were run in 3% agarose gels.
When necessary, PCR products were labeled in the presence of [a-P 32] dCTP
(NEN), by including 0.125 µI of a stock solution (3000 Ci/mmol) in a 10-µI PCR
reaction .

Radiolabeled DNA products were run in denaturing polyacrylamide

gels followed by an X-ray autoradiography with standard protocols [88].
Alternatively, unlabeled DNA products were run in nondenaturing polyacrylamide
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gels and silver stained with standard protocols [89]. Variant alleles between the
FVB/N and C3H mouse strains were analyzed with a set of 390 microsatellite
markers distributed along 20 mouse chromosomes; 272 microsatellite markers
were also tested between FVB/N and BU6 mouse strains.

All microsatellites

were analyzed in 3% agarose gels, or polyacrylamide gels were used to score
variant alleles in cases where difference in allele size was <6 bp.

Results and discussion

Of 390 markers tested between FVB/N and C3H mouse strains, 189 (48%)
were variant. Of 272 markers tested between FVB/N and BU6 mouse strains,
145 (53%) were variant.

Approximately half of the variant markers were

differentiable in 3% agarose gels, suggesting a difference in size of >6 bp. The
results are shown in Table 2.
This rate of variant alleles reported is comparable to that found between other
inbred laboratory mouse strains [65].

The results of this study provide the

information required to perform the QTL analysis and will be useful for other
investigators that would like to utilize the FVB/N inbred strain for genetic mapping
studies.
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Table 2. Variant alleles between FVB/N and the mouse strains C3He/FeJLe and
C57BU6J . C, C3He/FeJLe; B, C57BU6J; cM, map position in centimorgans;
-, no detected variant allele; >, variant allele size < 6 bp; >>, variant allele size ~
6 bp; +, PCR products were tested in polyacrylamide gels.
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B>>F
D15Mitl47 52.4
D15Mitl54 22.2 - B>>F
B>>F
D15Mitl72 57.8
D15Mitl73 63.4 - ·-·Dl5Mitl75 10.1 F>>C
D15Mltl91 51.7 D15Mitl92 52.3 - B>>F
Dl5Mitl93 60.0 F>.C
F>>C
DI5Mia17 57.8
\F>B
D15Mit244 58.9

-

-

.
-

-

-

38.0 C>F

D17Mit9 ·
D17Mitl8
D17Mitl9
D17Mit31
D17Mit41
D17Mit42
D17Mit45

29.4 C>F

DI7Mit93

60

-

57.0 26.2 F>>C

D17Mitl02
D17Mit106
D17Mitl33
D17Mitl35
D17Mit155
Dl7Mitl64
D17Mitl80
D17Mit221

..

Pg
B
C
21.0 26.0 F>>C F>>B

D16Mit6
D16Mit12
D16Mit15
Dl6Mitl9
D16Mit31
Dl6Mit38
D16Mit47
Dl6Mit~
D16Mit50
D16Mit64
D16Mit70
D16Mit71
D16Mit88
D16MiU31
D16Mit132
D16Mitl36
D16Mitl54
D16Nds2

17

F>B

Cm

30.0
54.0

10.7
28.0

-

F>>C F>>C F>>B

.

-

B>F
44.3 C>F
42.0 C>F
52.0 C>>F B>>F
38.0 C>>F B>>F
57.0 - B>>F
72.0 F>C F>B
9.7 C>F
6.8 C>F F>B
F>C F>B
C>F

3.4
28.0

4.0

C>F
-

-

-

F>>C

B>F

-

-•·

-~- .

···-

+··

-

-

16.4 C>>F B>>F

53.0
47.4

44.5

9.8

24.5
10.4

-

B>>F
C>F B>F

.

B>>F

17.0
F>B
55.7 C>>F

-

29.4 F>C
56.7 C>>F B>F
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Table 2 (continued)
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Dl8Mit3

54.0

-

-

D18¼t4
57.0 B>F
D18Mit14 18.0 C>F
Dl8Mitl9
2.0 C>>F
·D18Mit21 6.0 C>>F
D18Mit27
13.0 Dl8Mit31
4.0 F>C F>B
D18Mit33 44.0 F>>C Dl8Mit34 12.0 C>>F
D18Mit60
16-0 F>>C
D18Mit65
2.0 D18Mit123 31.0 C>F
..,
19

-

.

-·

+·
...

. ..

-

D19Mitl
D19Mitll
D19Mitl3
D19Mit15
Dl9Mit28
D19Mit31

52.0
41.0
33.0
16.4
12.0

- F>>B

-

F>>B

- F>>B
- F>>B

-

•

7.0
F>B
DI9Mit40 25.0 F>>C
16.0 C>>F B>>F
D19Mit41
Dl9Mit43 . 0.0
D19Mit61
9.8
Dl9M1t68
3.3
- B>>F
Dl9Mit71
55.7 F>>C
Dl9Mit79
8.7 F>C
D19Mit85
C>F F>B
D19Mit88 24.0 C>>F
D19Mit91 35.0 F>>C
X
DXMit79
56.0 C>F
DXMitl21 66.0 B>F ·.+.·
DXMit124
3.0 C>F
DXMlt140 19.0 C>F

-

-

I

Source: Neuhaus IM, Sommardahl CS, Johnson DK, Beier DR: Microsatellite
DNA variants between the FVB/N and C3HeB/FeJLe and C57BU6J mouse
strains. Mammalian Genome 8:506-509, 1997.
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Modifier Gene Detection and Interval Mapping in the orpk Mouse

Experimental design and phenotype scoring

Mice hemizygous for TgN737Rpw (Tg737/+) were selected from within the
orpk-F line and mated to C3H mice to obtain F1 progeny. These progeny were

genotyped at 21-24 days of age for TgN737Rpw and the mice that carried the
transgene were saved for the backcross and intercross matings. The backcross
was established between Tg737/+ orpk-F and F1 animals, the intercross was
established between Tg737/+ F1 animals. All progeny from these matings were
genotyped at 21-24 days of age for Tg737.

For the initial genome scan, 100

backcross progeny and 200 F2 progeny that were homozygous for the transgene
(Tg737/Tg737) were scored for the selected quantitative traits. These mice were

sacrificed at 27-35 days of age for the phenotype scoring. To assess the severity
of the kidney and liver phenotypes, the percentage of the kidney that is cystic
was measured as the kidney score and serum concentration of ALP was
measured as the liver score. Blood was collected postmortem via a cardiac
puncture, and

serum ALP

concentration

was

measured

by automated

biochemical analysis to obtain the liver score. A section of liver and kidney was
placed in 10% formalin for histological examination. The remainder of the liver
and the spleen were collected and snap frozen for DNA isolation. Hematoxylin
and eosin stained histological sections of kidney were used for morphometric
analysis of the kidney lesion. The percentage of the total area of kidney that is
cystic was measured using a computerized imaging system connected to a
videoscope (Bioquant, Nashville, TN). A cross-section and a longitudinal section
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of kidney were measured from each animal and the cystic percentages of these
two sections were summed to obtain the total percentage of cystic kidney (kidney
score). The distribution of the kidney and liver scores for the backcross progeny
analyzed have a mean that falls between the scores for the parental strains as
expected (Fig. 14). When comparing the kidney and liver scores for individual
animals, we found that there is not a correlation between the kidney score and
the liver score indicating that these traits may have different modifying genes.

PCR-based genotyping
Selective genotyping of the backcross progeny was used to expedite the
detection of the chromosomal location of the modifier genes that vary the severity
of the kidney and liver phenotypes. An end-mapping strategy was initially utilized
to determine which chromosomes might contain a QTL. This strategy generates
a series of chromosomal haplotypes for each selected progeny by typing only
markers at the ends of each chromosome and provides an efficient method for
excluding chromosomes that are unlikely to carry a QTL [74;90]. This method is
based on the fact that in affected animals carrying recessive mutations or QTL;
the chromosomal interval in which the QTL resides must be homozygous for the
affected (recessive) parental allele somewhere along its length. This interval will
be heterozygous along its length if an affected mouse carries a nonrecombinant
chromosomal interval from the unaffected (dominant) parental strain and that
chromosome cannot carry the QTL. The twenty backcross progeny with the
highest scores for the kidney and liver traits were typed using this method to
generate a cohort of candidate chromosomes for more detailed analysis.
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Figure 14. Mean kidney scores (top) and liver scores (bottom) for the backcross

progeny and the parental strains. Mean values are presented at the top of each
column and bars indicate the standard deviation of the mean.
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Selective genotyping was then performed with markers spaced 10-15 cM along
these chromosomes with the twenty progeny with the highest scores and the
twenty progeny with the lowest scores to confirm the presence of modifier loci.
Microsatellite markers whose FVB/N and C3H alleles differed in size by at
least 6 base pairs (bp) and that mapped to within 10 cM of the distal and
proximal ends of each chromosome were chosen for the end-mapping strategy.
Markers that mapped to 10-15 cM intervals spaced along the candid ate
chromosomes were chosen for the low resolution interval mapping study. These
microsatellite markers were chosen from the list of microsatellite markers that
were determined to be variant between the two strains.

PCR primer pairs for

these markers were purchased from Research Genetics, Inc. (Huntsville, AL,
USA). Genomic DNA was prepared from tail clips or liver tissue according to
standard protocols. PCR amplification was performed as described in the
previous section for each marker.

Analysis of genetic data and QTL analysis

Genotyping data obtained by analyzing the 20 backcross progeny with the
highest kidney scores and the 20 backcross progeny with the highest liver scores
for the markers known to map to the ends of each autosome were analyzed with
a software program developed by Neuhaus and Beier for interval haplotype
analysis [90]. The nonrandom distribution of haplotypes was evaluated by X 2
analysis. The randomness of loci distribution is normalized within a data set by
calculating it as a fraction of the maximum possible X2 (%max X2
chromosomal intervals with a %max X2 value of

)

[90]. The

> 0.60 were identified as

candidates for further analysis. This threshold was chosen based on the results
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described for this type of analysis with the average %max X2 value for intervals
carrying the selected homozygous loci was 0.98, while the average %max X2 for
the chromosomal intervals carrying unlinked loci was 0.40 [90].

For further

analysis of the candidate chromosomes, the 20 lowest scored progeny were
genotyped for the end markers and all 40 animals in each trait set were
genotyped for an additional 2-3 markers within each interval depending on the
size of the interval.

This genotyping data and quantitative trait scores were

analyzed initially using Map Manager QTb1968k [91]. To perform a more
accurate analysis, the data were analyzed using the latest version of
Mapmaker/QTL 1.1b [66]. These programs determine a maximum likelihood
linkage map and then use an interval mapping method to define the most likely
position and effects of a hypothesized QTL.

Results
Interval haplotype analysis of the genotyping data from the end mapping
strategy for the 20 backcross progeny with the most severe cystic kidneys
(kidney scores ranging from 11 .9% to 66.2%) identified seven chromosomal
intervals that may carry a candidate QTL. The 20 backcross progeny with the
mildest cystic kidneys (kidney scores ranging from 0.07% to 0.7%) were then
genotyped for the end markers and all 40 extreme progeny were genotyped for
two to three additional markers within the interval. Linkage analysis to individual
chromosomes was performed with Map Manager QTb and there were two
chromosomes found to have markers linked to the most severe cystic kidney
phenotype found in the backcross progeny. Three markers at the distal end of
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chromosome 4 have a significance of association (P<0.05); D4Mit16, D4Mit 54 ,
and D4Mit234. These markers flank an interval of 14 cM. Two markers at the
distal end of chromosome 17 have a significance of association (P<0.05) on
linkage analysis; D17Mit185 and D17Mit155.

These two markers flank an

interval of 14 cM . The backcross progeny genotype data and kidney scores were
then analyzed using the Mapmaker/QTL program for the low-resolution interval
mapping [66]. A LOO score threshold of 1 was used to identify intervals that
Inheritance of a FVB/N locus on

segregate with the quantitative trait.

chromosome 4 correlates with increased kidney score, with a X 2 of 12.158 and a
lad score of 2.64 for the interval between D4Mit54 and D4Mit234 (Fig . 15). This
5 cM interval explains 16.4% of the variance for kidney score in affected
backcross progeny. Inheritance of a FVB/N locus on chromosome 13 also
correlates with increased kidney score, with a X 2 of 6.705 and a lod score of 1.46
for the interval between D13Mit130 and D13Mit77 (Fig. 16). This 12 cM interval
explains 12.1% of the variance for kidney score in affected backcross progeny.
Inheritance of a FVB/N locus on chromosome 17 correlates with increased
kidney score, with X 2 of 7.641 and a lod score of 1.66 for the interval D17Mit185
and D17Mit155 (Fig . 17). This 15 cM interval explains 13.9% of the variance for
kidney score in affected backcross progeny.

Selective genotyping was

performed with the 40 extreme F2 progeny for the markers on chromosomes
4,13, and 17. Linkage analysis using Map Manager QTb with this data showed
the same three markers on distal chromosome 4 to have a significance of
association (P<0.05) with the severe cystic kidney phenotype.
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Figure 15.

LOO score values for intervals on chromosome 4

associated with cystic kidney disease severity in affected orpk mice,
calculated according to Mapmaker/QTL.
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Figure 16. LOO score values for intervals on chromosome 13 associated

with cystic kidney disease severity in affected orpk mice, calculated
according to Mapmaker/QTL.
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associated with cystic kidney disease severity in affected orpk mice,
calculated according to Mapmaker/QTL.
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Interval haplotype analysis of the genotyping data from the end mapping
strategy for the 20 backcross progeny with the highest serum ALP concentrations
(liver score ranging from 2452 to 3920) identified 5 chromosomal intervals that
may carry a candidate QTL. The 20 backcross progeny with the lowest serum
ALP concentrations (liver scores ranging from 279 to 791) were then genotyped
for the end markers, and all 40 extreme progeny were genotyped for two to three
additional markers within the interval. The data was analyzed with Map Manager
QTb for linkage to individual chromosomes.

The proximal marker on

chromosome 9, D9Mit43, was found to have a significance of association
(P<0 .05) with the backcross progeny having the highest serum ALP
concentrations. Low-resolution interval mapping was performed using the liver
scores and genotyping data with Mapmaker/QTL program.

A LOO score

threshold of 1 was set to identify intervals that segregate with the quantitative
trait. No significant intervals were found on this initial analysis.

Discussion
In stage 1 of our QTL analysis to detect potential modifier loci of the cystic
kidney phenotype, analysis of separate populations of severely affected and
mildly affected mice in the backcross progeny identified possible modifying loci
on chromosomes 4, 13 and 17.

A significant association of a recessively

inherited FVB/N-related locus on all three chromosomes with cystic kidney
disease severity was found . This confirms our hypothesis that there are several
modifying loci that influence the kidney phenotype between the C3H and FVB/N
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strains. Stage 2, the low-resolution interval mapping stage, was performed using
the Mapmaker/QTL program , because it is better designed to analyze the
extreme population data obtained by selective genotyping.

It is possible that

inheritance of each of these loci contributes to the variance in disease severity
seen . Inheritance of one or more of these loci may result in the more severe
cystic kidney phenotype as a result of a direct or indirect interaction between
their protein products and the Tg737 protein product. The interval that explains
most of the variance is at the distal end of chromosome 4 and has been found to
span an interval of 3 cM between D4Mit 54 and D4Mit 234. The lod score for
association with increased cystic kidney score for the backcross progeny was
found to be 2.64, which is consistent with linkage.

This interval was also

identified when analyzing the genotyping and the kidney score data from the F2
extreme progeny using the Map Manager QTb program for linkage analysis. The
fact that the markers for this interval segregated with the severe kidney scores
with both populations makes it a strong candidate to contain a modifier gene. A
modifier locus that strongly modulates the progression of the polycystic kidney
phenotype in pcy and cpk mice was also mapped to chromosome 4 [83;84].
However, this locus is 30 cM proximal to the locus identified in our search.
Further analysis of all three intervals will be performed by genotyping more
backcross and F2 progeny for the flanking markers to strengthen the LOO score
of association for each interval. Also, markers identified as polymorphic between
the parental strains and that map within the intervals will be used to further define
the interval.
The search for modifier loci that control the liver trait detected a nonrandom
segregation of one marker on chromosome 9 that segregated with the highest
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liver scores. Low-resolution interval mapping using the Mapmaker/QTL program
failed to identify any significant associations, however.

This is felt to be due to

the small number of animals being used in the analysis, and possible to weaker
modifier loci. Further analysis using more backcross progeny will be performed
for the chromosomal intervals identified by interval haplotype analysis.
Increasing the number of animals genotyped for the selected markers flanking
these chromosomal intervals should strengthen the ability to identify modifier loci.
We hypothesize that the modifier loci will be different for the liver and kidney
traits since there is not a correlation between the kidney score and the liver score
for the backcross progeny or F2 progeny analyzed.
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V. SUMMARY
The aim of determining the effect of paclitaxel on cystic kidney and liver
lesions in the orpk mutant line lead to several conclusions. Taxol has no effect
on the cystic kidney disease progression in the orpk mutants at a dose effective
in the cpk mutants. Taxol has no effect on the targeting of the EGFR in the renal
cystic epithelial cells.

Taxol has no effect on the proliferation and

dedifferentiation of the biliary ductules in the orpk mutants. These results may be
due to the differences in the two mutations at the molecular and cellular levels.
Also, the disease conditions have a different progression of the renal pathology,
and different multiorgan histopathology. In addition, the orpk mutation is on the
FVB/N genetic background while the cpk mutation is on a C57BU6 genetic
background, raising the possibility that genetic background may have an
influence on the effectiveness of taxol as a therapeutic agent.

Additional

experiments with the orpk mutation on the C57BU6 would address this
possibility. Since publication of our study in Pediatric Nephrology 11 :728-733,
1997; taxol has been shown to have no effect on the progression of PKO in the
Han:SPRO-Cy rat model of PKO nor in the pcy mouse model of PKO [56]. On
the basis of these three studies in rodents, it appears that taxol has limited
potential usefulness as a therapeutic agent in the treatment of PKO.
The aim of identifying the phenotypic variations of the orpk mutation on the
C3H genetic background showed major phenotypic variations in the kidney, liver,
and pancreatic lesions. The significant differences in the lesions suggest the
presence of important modifier genes that vary in the FVB/N and C3H genetic
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backgrounds. These differences were evident in the first generation backcross to
C3H indicating that the modifier genes may be dominant in the C3H background .
Percent of the kidney area that is cystic was selected as a quantitative trait
reflecting the kidney phenotype and serum concentration of ALP was selected as
a quantitative trait reflecting the liver phenotype since there was significant
differences in these values between the orpk-F and orpk-C mutant animals.
These quantitative traits were utilized to identify the chromosomal location of the
modifier genes.
The aim of identifying the chromosomal location of the modifier genes that
vary the cystic kidney phenotype between the C3H and FVB/N genetic
backgrounds has been accomplished . The next step is to begin Stage 3 of the
QTL analysis, the single-QTL-oriented fine mapping stage.

The basis for this

stage is analysis of recombinants within an interval previously found to contain
the modifier gene.

The experimental designs for this stage require the

generation of thousands of progeny; therefore, is a very lengthy process. Since
the ultimate goal is to get from fine mapping to the gene itself, therefore an
alternative to linkage analysis, is to search for expressed sequences mapping
within the intervals found to contain modifier loci. This approach requires the
region to be defined to < 1 cM and can still be difficult if many genes map to the
region .

Potential candidates identified can be tested for expression patterns

appropriate for the kidney phenotype. In addition, DNA sequencing will identify
polymorphisms between the C3H and FVB/N alleles of any candidate gene. An
initial search of databases available for the mouse genome has been performed
for the chromosomal intervals identified to contain potential modifier loci of the
cystic kidney phenotype. There are several genes within each interval that could
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be a candidate modifier, but not one that is an obvious standout.

Within the

strongest interval on chromosome 4, between D4Mit54 and D4Mit234, there are
cell division cycle genes, G-protein related genes, and phospholipase A2 genes
that could play a role in the pathogenesis of the cyst formation via cell signaling
pathways. This region shows conserved synteny with the human chromosomal
region 1p36-34, and this human chromosomal region also contains many genes
that could play a role in cystogenesis.

Further narrowing of the interval and

research on the genes within the interval are needed before a candidate gene
can be identified .

The aim for the future of this project is to identify these

candidate genes and prove their function as modifiers of the orpk cystic kidney
phenotype.

Identification of modifier genes will provide information into the

pathogenesis of polycystic kidney disease. Understanding of the molecular and
cellular nature of these modifying genes can lead to targets for diagnostics or
therapeutics for polycystic kidney disease.
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